Ardelyx Stock Price

0.0378 (4.61%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 2,427,264
Bid Price 0.8081
Ask Price 0.858
News -
Day High 0.87


52 Week Range


Day Low 0.7301
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ardelyx Inc ARDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0378 4.61% 0.8578 20:00:00
Open Price Low Price High Price Close Price Prev Close
0.75 0.7301 0.87 0.853 0.82
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,930 2,427,264 $ 0.7934285 $ 1,925,860 - 0.4902 - 1.92
Last Trade Time Type Quantity Stock Price Currency
18:46:52 formt 100 $ 0.8578 USD


Draw Mode:

Ardelyx Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 124.04M 144.60M 143.08M $ 10.10M $ - -1.52 -0.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 1.07M 3.70%

more financials information »

Ardelyx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ARDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.710.870.660.74919111,594,4290.147820.82%
1 Month0.670.870.63160.71204241,523,3520.187828.03%
3 Months0.70380.870.49020.63318472,379,3890.15421.88%
6 Months0.81731.380.49020.81488593,024,3480.04054.96%
1 Year1.601.920.49021.236,860,131-0.7422-46.39%
3 Years2.2810.43430.49022.423,532,050-1.42-62.38%
5 Years4.8010.43430.49022.592,292,547-3.94-82.13%

Ardelyx Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now